Company research
ELUTIA INC.
CIK 1708527Updated Nov 13, 2026
SecurityELUT · NASDAQ · equity
Name history
AZIYO BIOLOGICS, INC. · through Aug 14, 2023
ELUT price & chart
Loading TradingView…
NASDAQ:ELUT on TradingView ↗About the company
Elutia Inc. (Nasdaq: ELUT) is a drug delivery company built to stop surgical infections. The Company developed and launched EluPro, the first antibiotic-eluting bioenvelope designed to protect patients receiving pacemakers and defibrillators, and in 2025 sold that business to Boston Scientific Corporation. Elutia’s lead program, NXT-41x, builds on the same drug-eluting platform and is designed to deliver two powerful antibiotics directly to the surgical site, stopping infection before it starts. Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www. Elutia.com.
In the news
Seeking Alpha
Elutia Inc. 2026 Q3 - Results - Earnings Call Presentation ↗
Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript ↗
Elutia Inc. 2026 Q2 - Results - Earnings Call Presentation ↗
SEC disclosures
ELUTIA INC. files 8-K: Material Event ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 29,407,000Source | 48,407,000Source | 43,649,000Source | 33,849,000Source | 41,904,000Source | 55,209,000Source | 39,298,000Source | — | 62,350,000Source | 36,127,000Source | 43,428,000Source | 68,841,000Source |
| Property, Plant and Equipment, NetUSD | 2,054,000Source | 693,000Source | 2,922,000Source | 2,071,000Source | 159,000Source | 2,909,000Source | 1,031,000Source | — | 2,511,000Source | 773,000Source | 172,000Source | 1,403,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,800,000Source | 9,123,000Source | 990,000Source | 6,575,000Source | 9,972,000Source | 1,260,000Source | 7,424,000Source | — | 1,529,000Source | 8,273,000Source | 11,671,000Source | 15,069,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,721,000Source | 25,741,000Source | 19,896,000Source | 8,500,000Source | 18,188,000Source | 28,488,000Source | 17,358,000Source | — | 36,350,000Source | 13,239,000Source | 19,276,000Source | 16,989,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,553,000Source | 2,931,000Source | 1,438,000Source | 3,150,000Source | 3,518,000Source | 2,068,000Source | 2,860,000Source | — | 1,734,000Source | 2,276,000Source | 3,263,000Source | 6,830,000Source |
| Inventory, NetUSD | 2,011,000Source | 3,633,000Source | 2,649,000Source | 5,243,000Source | 3,115,000Source | 2,657,000Source | 4,286,000Source | — | 2,617,000Source | 3,911,000Source | 3,853,000Source | 10,052,000Source |
| Assets, CurrentUSD | 18,378,000Source | 37,318,000Source | 37,215,000Source | 22,280,000Source | 30,351,000Source | 48,591,000Source | 30,017,000Source | — | 55,818,000Source | 26,172,000Source | 31,253,000Source | 50,699,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 539,000Source | 431,000Source | 1,378,000Source | 1,090,000Source | 1,109,000Source | 2,030,000Source | 1,620,000Source | — | 2,271,000Source | 1,986,000Source | 2,165,000Source | 3,015,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 1,400,000Source | — | 2,300,000Source | 1,400,000Source | — | — | — | 2,426,000Source | 860,000Source | 271,000Source | 1,576,000Source |
| Other Assets, NoncurrentUSD | 2,565,000Source | 1,273,000Source | 2,522,000Source | 2,923,000Source | 1,422,000Source | 2,449,000Source | 826,000Source | — | 2,492,000Source | 909,000Source | 332,000Source | 1,670,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 73,325,000Source | 88,645,000Source | 27,903,000Source | 75,692,000Source | 106,242,000Source | 32,682,000Source | 75,756,000Source | — | 34,678,000Source | 82,387,000Source | 82,028,000Source | 73,874,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 203,044,000Source | 180,260,000Source | 207,030,000Source | 201,251,000Source | 157,452,000Source | 206,165,000Source | 197,027,000Source | — | 203,842,000Source | 183,298,000Source | 137,021,000Source | 132,939,000Source |
| Retained Earnings (Accumulated Deficit)USD | -247,004,000Source | -220,532,000Source | -191,328,000Source | -243,136,000Source | -221,818,000Source | -183,682,000Source | -233,526,000Source | — | -176,213,000Source | -229,593,000Source | -175,644,000Source | -137,988,000Source |
| Stockholders' Equity Attributable to ParentUSD | -43,918,000Source | -40,238,000Source | 15,746,000Source | -41,843,000Source | -64,338,000Source | 22,527,000Source | -36,458,000Source | -50,299,000Source | 27,672,000Source | -46,260,000Source | -38,600,000Source | -5,033,000Source |
| Liabilities and EquityUSD | 29,407,000Source | 48,407,000Source | 43,649,000Source | 33,849,000Source | 41,904,000Source | 55,209,000Source | 39,298,000Source | — | 62,350,000Source | 36,127,000Source | 43,428,000Source | 68,841,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 41,334,000Source | 39,678,000Source | 21,045,000Source | 37,948,000Source | 39,808,000Source | 23,725,000Source | 36,851,000Source | — | 25,139,000Source | 37,795,000Source | 43,037,000Source | 42,615,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 355,000Source | 460,000Source | 275,000Source | 682,000Source |
| Accounts Payable, CurrentUSD | 6,598,000Source | 5,073,000Source | 3,531,000Source | 6,074,000Source | 3,140,000Source | 3,870,000Source | 4,516,000Source | — | 4,791,000Source | 4,149,000Source | 2,285,000Source | 2,328,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,814,000Source | — | 3,695,000Source | 2,716,000Source | — | 3,695,000Source | 319,000Source | — | 3,587,000Source | 423,000Source | — | 956,000Source |
| Other Liabilities, NoncurrentUSD | — | 1,555,000Source | — | — | 1,571,000Source | — | — | — | — | — | 515,000Source | 127,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,274,000Source | 5,425,000Source | 4,798,000Source | 6,304,000Source | 7,335,000Source | 5,815,000Source | 6,092,000Source | — | 4,352,000Source | 7,104,000Source | 9,485,000Source | 10,103,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 21,103,000Source | 22,641,000Source | — | 21,370,000Source | 18,873,000Source | — | 21,762,000Source | — | — | 22,603,000Source | 20,356,000Source | 24,260,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | — | —Source | —Source | — | —Source | — | — | — | — | — |
| Long-term Debt, Current Maturities | —Source | — | — | —Source | —Source | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -7,469,000Source | -3,933,000Source | 53,380,000Source | -53,949,000Source | -37,656,000Source | -32,897,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 330,000Source | 868,000Source | 2,785,000Source | 3,451,000Source | 3,748,000Source | 3,733,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 931,000Source | 1,211,000Source | 5,214,000Source | 7,891,000Source | 2,437,000Source | 3,647,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 334,000Source | 584,000Source | -84,000Source | -527,000Source | -802,000Source | 834,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 40,000Source | 375,000Source | 1,641,000Source | 58,000Source | 609,000Source | 498,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,831,000Source | -8,881,000Source | -44,810,000Source | -22,657,000Source | -21,761,000Source | -21,434,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -34,000Source | -278,000Source | 78,559,000Source | -474,000Source | 14,208,000Source | -540,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 459,000Source | 278,000Source | 1,876,000Source | 654,000Source | 346,000Source | 540,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 44,000Source | 152,000Source | 380,000Source | 1,188,000Source | 32,000Source | 395,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,000Source | 13,278,000Source | -10,638,000Source | 17,094,000Source | 9,840,000Source | 8,535,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 18,615,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,721,000Source | 25,741,000Source | 19,896,000Source | 8,500,000Source | 28,488,000Source | 17,358,000Source | 36,350,000Source | 13,239,000Source | 19,276,000Source | 16,989,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 526,000Source | 7,492,000Source | 5,288,000Source | 2,321,000Source | 5,480,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,335,000Source | 1,530,000Source | 905,000Source | 1,029,000Source | 931,000Source | 1,088,000Source | 4,397,000Source | 7,891,000Source | 2,405,000Source | 3,647,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 53,000Source | — | 216,000Source | 216,000Source | 115,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | 849,000Source | — | — | — | — | 1,100,000Source | 3,400,000Source | 3,398,000Source | 3,397,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 100,000Source | 300,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | 425,000Source | — | 80,211,000Source | 180,000Source | 7,529,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -1,287,000Source | — | — | -311,000Source |
| General and Administrative ExpenseUSD | — | — | 3,519,000Source | 4,340,000Source | 3,454,000Source | 3,552,000Source | 4,091,000Source | 3,721,000Source | 15,080,000Source | 18,659,000Source | 14,104,000Source | 16,627,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -383,000Source | 3,339,000Source | -7,646,000Source | -7,091,000Source | -7,894,000Source | -1,887,000Source | -15,871,000Source | -54,129,000Source | -41,249,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,485,000Source | -2,053,000Source | — | -2,519,000Source | 425,000Source | -2,046,000Source | 69,251,000Source | 180,000Source | 3,593,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 8,000Source | 8,000Source | 8,000Source | 70,000Source | 8,000Source | 13,000Source | 7,000Source | 28,000Source | 34,000Source |
| InterestExpenseNonoperatingUSD | — | — | 265,000Source | 131,000Source | — | 518,000Source | — | 1,085,000Source | — | 4,779,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,868,000Source | 1,286,000Source | -7,646,000Source | -9,610,000Source | -7,469,000Source | -3,933,000Source | 53,380,000Source | -53,949,000Source | -37,656,000Source | -32,897,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,868,000Source | 1,067,000Source | — | -9,610,000Source | — | -3,933,000Source | 53,380Source | -53,949,000Source | -37,656,000Source | -32,897,000Source |
| Operating ExpensesUSD | — | — | 7,061,000Source | 10,966,000Source | 9,404,000Source | 9,818,000Source | 8,150,000Source | 8,159,000Source | 33,507,000Source | 46,358,000Source | 41,579,000Source | 50,962,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 58,000Source | -1,442,000Source | 71,000Source | -105,000Source | -2,758,000Source | 1,186,000Source | -4,899,000Source | 4,159,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 468,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | — | 78,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,323,000Source | 3,662,000Source | 2,427,000Source | 2,747,000Source | 3,114,000Source | 2,951,000Source | 12,293,000Source | 24,375,000Source | 24,745,000Source | 49,187,000Source |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of RevenueUSD | — | — | 1,470,000Source | 1,871,000Source | 980,000Source | 1,294,000Source | 1,312,000Source | 1,569,000Source | 5,697,000Source | 13,668,000Source | 13,692,000Source | 29,965,000Source |
| Operating Income (Loss)USD | — | — | -5,208,000Source | -9,175,000Source | -7,957,000Source | -8,365,000Source | -6,348,000Source | -6,777,000Source | -26,911,000Source | -35,651,000Source | -30,526,000Source | -31,740,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 58,000Source | -1,442,000Source | 71,000Source | -105,000Source | -2,758,000Source | 1,186,000Source | -4,899,000Source | 4,159,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -375,000Source | 3,347,000Source | -7,638,000Source | -7,083,000Source | -7,824,000Source | -1,879,000Source | -15,858,000Source | -54,122,000Source | -41,221,000Source | -32,863,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 8,000Source | 8,000Source | 8,000Source | 70,000Source | 8,000Source | 13,000Source | 7,000Source | 28,000Source | 34,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,868,000Source | 1,286,000Source | -7,646,000Source | -9,610,000Source | -7,469,000Source | -3,933,000Source | 53,380,000Source | -53,949,000Source | -37,656,000Source | -32,897,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.09Source | 0.03Source | -0.17Source | -0.23Source | -0.17Source | -0.1Source | 1.29Source | -1.86Source | -2.07Source | -2.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.33Source | -0.17Source | -0.26Source | -0.17Source | -0.21Source | 0.87Source | -1.86Source | -2.07Source | -2.38Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 42,431,314Source | 32,520,134Source | 44,223,722Source | 41,782,556Source | 42,998,504Source | 38,616,207Source | 41,416,850Source | 29,071,113Source | 18,160,822Source | 13,832,887Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 46,957,199Source | 35,520,938Source | 44,223,722Source | 46,308,642Source | 42,998,504Source | 42,913,111Source | 45,942,787Source | 29,071,113Source | 18,160,822Source | 13,832,887Source |
| Interest Expense (non-operating)USD | — | — | 265,000Source | 131,000Source | — | 518,000Source | — | 1,085,000Source | — | 4,779,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | 849,000Source | — | — | — | — | 1,100,000Source | 3,400,000Source | 3,398,000Source | 3,397,000Source |
| General and Administrative ExpenseUSD | — | — | 3,519,000Source | 4,340,000Source | 3,454,000Source | 3,552,000Source | 4,091,000Source | 3,721,000Source | 15,080,000Source | 18,659,000Source | 14,104,000Source | 16,627,000Source |
| Gross ProfitUSD | — | — | 1,853,000Source | 1,791,000Source | 1,447,000Source | 1,453,000Source | 1,802,000Source | 1,382,000Source | 6,596,000Source | 10,707,000Source | 11,053,000Source | 19,222,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -383,000Source | 3,339,000Source | -7,646,000Source | -7,091,000Source | -7,894,000Source | -1,887,000Source | -15,871,000Source | -54,129,000Source | -41,249,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.01Source | 0.1Source | -0.17Source | -0.17Source | -0.18Source | -0.05Source | -0.38Source | -1.86Source | -2.27Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.12Source | -0.27Source | -0.17Source | -0.2Source | -0.18Source | -0.17Source | -0.64Source | -1.86Source | -2.27Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,485,000Source | -2,053,000Source | — | -2,519,000Source | 425,000Source | -2,046,000Source | 69,251,000Source | 180,000Source | 3,593,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 5,796,000Source | 5,282,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | 35,000Source | 491,000Source | 108,000Source | -184,000Source | 387,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,868,000Source | 1,067,000Source | — | -9,610,000Source | — | -3,933,000Source | 53,380Source | -53,949,000Source | -37,656,000Source | -32,897,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | -383,000Source | 3,120,000Source | — | -9,610,000Source | — | — | — | -54,129,000Source | -41,249,000Source | — |
| Operating ExpensesUSD | — | — | 7,061,000Source | 10,966,000Source | 9,404,000Source | 9,818,000Source | 8,150,000Source | 8,159,000Source | 33,507,000Source | 46,358,000Source | 41,579,000Source | 50,962,000Source |
| Research and Development ExpenseUSD | — | — | 1,088,000Source | 702,000Source | 2,527,000Source | 989,000Source | 1,973,000Source | 871,000Source | 4,163,000Source | 3,785,000Source | 4,399,000Source | 8,940,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 3,323,000Source | 3,662,000Source | 2,427,000Source | 2,747,000Source | 3,114,000Source | 2,951,000Source | 12,293,000Source | 24,375,000Source | 24,745,000Source | 49,187,000Source |
| Selling and Marketing ExpenseUSD | — | — | 1,601,000Source | 1,241,000Source | 1,366,000Source | 1,273,000Source | 1,480,000Source | 995,000Source | 5,765,000Source | 12,546,000Source | 13,087,000Source | 20,195,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
elut-ex99d1.htm · 8-K · 2026-11-05
Exhibit 99.1 Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection rates reported as high as 23%. NXT-41x In Vivo Study Supports…
Read attachment ↗elut-20260817xex99d1.htm · 8-K · 2026-08-21
EX-99.1 2 elut-20260817xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed t…
Read attachment ↗elut-20260817xex99d2.htm · 8-K · 2026-08-21
EX-99.2 3 elut-20260817xex99d2.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On August 17, 2026, Elutia Inc. (the “Company”) completed the previously announced sale of its Women’s Health segment (the “SimpliDerm Business”) to Cellution Biologics Inc. (“Cellution Biologics” or the “Buyer”). The sale (the “SimpliDerm Sale”) was structured as an asset sale, which occurred by divestiture of substantially all of the assets related to the Company’s bus…
Read attachment ↗elut-20260630xex4d10.htm · 10-Q · 2026-08-14
Exhibit 4.10 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPINION OF COUNSEL IN A FORM REASONABLY ACCEPTABLE TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED …
Read attachment ↗elut-20260630xex4d11.htm · 10-Q · 2026-08-14
Exhibit 4.11 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPINION OF COUNSEL IN A FORM REASONABLY ACCEPTABLE TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED …
Read attachment ↗elut-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 elut-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk ────────────────────────…
Read attachment ↗